Why the study?
Improved cancer life expectancy has increased the importance of short- and long-term cardiac side effects, necessitating practical guidance on echocardiographic screening for cardiotoxicity.
This review highlights echocardiography as the most established and practical tool for screening and detecting cardiotoxicity in patients receiving oncology treatments.
Echocardiography remains the most feasible cardiotoxicity screen; leaves open optimal protocols amid expanding oncology survivorship.
As advances in oncology therapies lead to significant improvement in life expectancy of many cancer entities, short-, and long-term cardiac side effects of oncology treatments gain increasing importance. In search of new screening modalities, echocardiography currently presents the best established and clinically easily feasible tool to detect cardiotoxicity in patients undergoing cancer therapy. This review focusses on the most commonly used oncology therapies and aims to give a practical approach to guide clinicians caring for this growing number of patients.
No takes yet. Share an insight, caveat, or question.
Frey et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: